Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Zoeken op expertise, naam of affiliatie
Treatment of melanoma in-transit metastases confined to the limb
A. M.M. Eggermont
, P. M. Schlag
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
peer review
64
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Treatment of melanoma in-transit metastases confined to the limb'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
In-transit Metastasis
100%
Isolated Limb Perfusion
100%
Melanoma Treatment
100%
Melphalan
50%
Perfusion
50%
Primary Tumor
33%
Interferon-α (IFN-α)
33%
Tumor Necrosis Factor-α
33%
Overall Response Rate
33%
Response Rate
33%
Isolated Limb Infusion
33%
Intra-arterial Chemotherapy
33%
Intralesional Injection
33%
Tumor
16%
Europe
16%
Effective Therapy
16%
Multiple Lesions
16%
Survival Benefit
16%
Melanoma
16%
Interferon-γ
16%
Local Control
16%
Local Relapse
16%
Complete Response Rate
16%
% Response
16%
Hyperthermia
16%
Locoregional Treatment
16%
Excision
16%
Melanoma Patients
16%
Surgical Excision
16%
Local Tumor Control
16%
Regional Chemotherapy
16%
Perfusion System
16%
Carbon Dioxide Laser
16%
Systemic Metastasis
16%
Recurrence-free Interval
16%
Small Nodules
16%
Recurrent Melanoma
16%
Tourniquet
16%
Satellitosis
16%
Laser Evaporation
16%
Extracorporeal Perfusion
16%
Subcutaneous Nodules
16%
Medicine and Dentistry
In-Transit Metastasis
100%
Limb
100%
Limb Perfusion
100%
Melanoma
100%
Melphalan
50%
Neoplasm
33%
Primary Tumor
33%
Recurrent Disease
33%
Tumor Necrosis Factor
33%
Infusion
33%
Intralesional Drug Administration
33%
Interferon
33%
Intraarterial Drug Administration
33%
Disease
16%
Metastatic Carcinoma
16%
Hyperthermia
16%
Gamma Interferon
16%
Carbon Dioxide Laser
16%
Regional Perfusion
16%
Subcutaneous Nodule
16%
Extracorporeal Circulation
16%